From what 0 stock analysts predict, the share price for Coursera, Inc. (COUR) might increase by 113.69% in the next year. This is based on a 12-month average estimation for COUR. Price targets go from $9 to $30. The majority of stock analysts believe COUR is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Coursera, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Coursera, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of COUR.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Nafeesa Gupta B of A Securities | Buy | $11 | Initiates | Sep 19, 2024 |
Jeffrey Silber BMO Capital | Outperform | $11 | Maintains | Jul 26, 2024 |
Brett Knoblauch Cantor Fitzgerald | Overweight | $22 | Maintains | Jul 26, 2024 |
Eric Sheridan Goldman Sachs | Sell | $9 | Maintains | Jul 26, 2024 |
Rishi Jaluria RBC Capital | Outperform | $18 | Reiterates | Jul 26, 2024 |
Ryan MacDonald Needham | Buy | $15 | Reiterates | Jul 26, 2024 |
Sarang Vora Telsey Advisory Group | Outperform | $18 | Maintains | Jul 26, 2024 |
Sarang Vora Telsey Advisory Group | Outperform | $18 | Maintains | Jul 22, 2024 |
Jason Celino Keybanc | Overweight | $12 | Maintains | Jul 22, 2024 |
Ryan MacDonald Needham | Buy | $15 | Reiterates | May 17, 2024 |
Jeffrey Silber BMO Capital | Outperform | $13 | Maintains | May 1, 2024 |
Eric Sheridan Goldman Sachs | Sell | $10.5 | Maintains | May 1, 2024 |
Ryan MacDonald Needham | Buy | $15 | Maintains | Apr 30, 2024 |
Brett Knoblauch Cantor Fitzgerald | Overweight | $21 | Maintains | Apr 30, 2024 |
Josh Baer Morgan Stanley | Overweight | $15 | Maintains | Apr 30, 2024 |
Sarang Vora Telsey Advisory Group | Outperform | $18 | Maintains | Apr 30, 2024 |
Rishi Jaluria RBC Capital | Outperform | $18 | Maintains | Apr 30, 2024 |
Terry Tillman Truist Securities | Hold | $12 | Maintains | Apr 30, 2024 |
Sarang Vora Telsey Advisory Group | Outperform | $25 | Maintains | Apr 25, 2024 |
Jason Celino Keybanc | Overweight | $20 | Maintains | Apr 24, 2024 |
When did it IPO
2021
Staff Count
1,295
Country
United States
Sector/Industry
Consumer Defensive/Education & Training Services
CEO
Mr. Jeffrey Nacey Maggioncalda
Market Cap
$1.16B
In 2023, COUR generated $635.8M in revenue, which was a increase of 21.39% from the previous year. This can be seen as a signal that COUR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Coursera (COUR) has experienced positive momentum after a significant decline, with shares down 82% from their initial public offering price of $39 since March 2021.
Why It Matters - Coursera's positive momentum signals a potential recovery, which could attract investors looking for undervalued stocks and opportunities in the ed-tech sector.
Summary - Coursera has announced an advisory release for Coursera Connect 2024 in Mountain View, California.
Why It Matters - Coursera's new initiative, Connect 2024, could enhance its market position and growth potential, impacting its stock performance and attractiveness to investors.
Summary - AI's job impact may boost higher education, benefiting Coursera, which has strong cash reserves and low debt. However, risks include cash management and job placement effectiveness.
Why It Matters - Coursera's alignment with AI-driven education trends and strong financials suggest growth potential, while risks around job placement efficacy and cash management warrant close monitoring.
Summary - Moderna and Coursera have partnered to launch a free course on mRNA medicines, aiming to enhance STEM education and address workforce readiness gaps.
Why It Matters - The partnership between Moderna and Coursera enhances workforce readiness in biotech, potentially boosting interest and investment in mRNA technologies, influencing stock performance of both companies.
Summary - Coursera exceeded quarterly expectations, driven by high AI course enrollment. The stock is currently undervalued, and the company maintains a strong financial position.
Why It Matters - Coursera's strong earnings and rising AI course enrollment signal growth potential, while its undervalued stock and solid financial health present an attractive investment opportunity.
Summary - Coursera has a buy rating, with expected growth accelerating to mid-teens in the next two years. Q2 2024 revenue rose 11% y/y, driven by consumer segment performance.
Why It Matters - Coursera's buy rating and projected mid-teens growth indicate strong revenue potential, particularly in consumer segments, suggesting favorable returns and increased investor confidence.